Literature DB >> 24554520

Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma.

Qiang Liu1, Mulati Rexiati, Ying Yang, Wen-Guang Wang, Baihetiya Azhati, Weilijiang Saimaiti, Yu-Jie Wang.   

Abstract

Chemokines and their receptors are known to play important roles in tumor growth and metastasis of many malignancies. Recently, CC chemokine receptor 4 (CCR4) has been described as a prognostic marker in various tumors. However, the possible role of CCR4 in clear cell renal cell carcinoma (ccRCC) has not been well elucidated. In this study, we detected the expression of CCR4 in 53 ccRCC by immunohistochemistry and correlated it with clinicopathological parameters and prognosis. Immunohistochemistry was used to determine the expression of CCR4 in 53 ccRCC and 11 renal contusion tissue specimens. CCR4 expression between carcinoma and normal renal tissues was evaluated by χ(2) test. Correlation between CCR4 and clinicopathological data was tested by χ(2) test. Univariate survival analysis was performed by the Kaplan-Meier method, and differences among the groups were analyzed by the log-rank test. CCR4 expression in ccRCC tissue was significantly higher compared with normal renal tissue samples (χ(2) = 4.392, P = 0.036). CCR4 was correlated with the clinicopathological features including tumor stage (P = 0.009), lymph node metastasis (P = 0.003) and distant metastasis (P = 0.031). Further, CCR4 was the only dependent affecting factor in lymph node metastasis (P = 0.014). Univariate analysis showed that tumor stage, lymph node metastasis, distant metastasis and CCR4 were influential factors for poor prognosis in ccRCC patients; multivariate analysis revealed that CCR4 (P = 0.007) was the only independent risk factor for prognosis. In addition, Kaplan-Meier curve for overall survival (OS) indicated that prognosis was unfavorable for patients who had high CCR4 expression level (P = 0.010). CCR4 was correlated with tumor aggressive behavior in ccRCC. It might be involved in lymph node metastasis and have influence on patients' OS. Further research is needed to determine the potential of CCR4.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24554520     DOI: 10.1007/s12032-014-0882-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

Review 1.  Immunopathogenesis of lymphoma: focus on CCR4.

Authors:  Takashi Ishida; Ryuzo Ueda
Journal:  Cancer Sci       Date:  2010-11-02       Impact factor: 6.716

2.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.

Authors:  Kazuhito Yamamoto; Atae Utsunomiya; Kensei Tobinai; Kunihiro Tsukasaki; Naokuni Uike; Kimiharu Uozumi; Kazunari Yamaguchi; Yasuaki Yamada; Shuichi Hanada; Kazuo Tamura; Shigeo Nakamura; Hiroshi Inagaki; Koichi Ohshima; Hitoshi Kiyoi; Takashi Ishida; Kouji Matsushima; Shiro Akinaga; Michinori Ogura; Masao Tomonaga; Ryuzo Ueda
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

Review 3.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

4.  The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer.

Authors:  Ji-Yu Li; Zhou-Luo Ou; San-Jian Yu; Xiao-Li Gu; Chen Yang; Ao-Xiang Chen; Gen-Hong Di; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2011-04-09       Impact factor: 4.872

5.  Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.

Authors:  Sujata Patil; Nicole Ishill; John Deluca; Robert J Motzer
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

6.  Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs.

Authors:  Arya Biragyn; Monica Bodogai; Purevdorj B Olkhanud; Sinan R Denny-Brown; Nitin Puri; Koichi Ayukawa; Shiro Kanegasaki; Cory M Hogaboam; Katarzyna Wejksza; Catalina Lee-Chang
Journal:  J Immunother       Date:  2013-05       Impact factor: 4.456

Review 7.  Renal cell carcinoma.

Authors:  Brian I Rini; Steven C Campbell; Bernard Escudier
Journal:  Lancet       Date:  2009-03-05       Impact factor: 79.321

8.  Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype.

Authors:  Jun Wang; Liqiang Xi; Jennifer L Hunt; William Gooding; Theresa L Whiteside; Zhuo Chen; Tony E Godfrey; Robert L Ferris
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

9.  Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma.

Authors:  Takahiro Tsujikawa; Tomonori Yaguchi; Gaku Ohmura; Shigeki Ohta; Asuka Kobayashi; Naoshi Kawamura; Tomonobu Fujita; Hiroshi Nakano; Taketoshi Shimada; Takeshi Takahashi; Ryuta Nakao; Akio Yanagisawa; Yasuo Hisa; Yutaka Kawakami
Journal:  Int J Cancer       Date:  2012-12-17       Impact factor: 7.396

10.  HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.

Authors:  Hans-Henning Schmidt; Yingzi Ge; Felix J Hartmann; Heinke Conrad; Felix Klug; Sina Nittel; Helga Bernhard; Christoph Domschke; Florian Schuetz; Christof Sohn; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2013-05-15       Impact factor: 8.110

View more
  6 in total

1.  Chemokine CCL17 induced by hypoxia promotes the proliferation of cervical cancer cell.

Authors:  Li-Bing Liu; Feng Xie; Kai-Kai Chang; Wen-Qing Shang; Yu-Han Meng; Jia-Jun Yu; Hui Li; Qian Sun; Min-Min Yuan; Li-Ping Jin; Da-Jin Li; Ming-Qing Li
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

2.  A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.

Authors:  Chiara Berlato; Moddasar N Khan; Tiziana Schioppa; Richard Thompson; Eleni Maniati; Anne Montfort; Maryam Jangani; Monica Canosa; Hagen Kulbe; Urs B Hagemann; Alexander R Duncan; Laura Fletcher; Robert W Wilkinson; Thomas Powles; Sergio A Quezada; Frances R Balkwill
Journal:  J Clin Invest       Date:  2017-01-30       Impact factor: 14.808

3.  High CCR4 expression in the tumor microenvironment is a poor prognostic indicator in lung adenocarcinoma.

Authors:  Takahiro Karasaki; Guangliang Qiang; Masaki Anraku; Yanbin Sun; Aya Shinozaki-Ushiku; Eiichi Sato; Kosuke Kashiwabara; Kazuhiro Nagayama; Jun-Ichi Nitadori; Masaaki Sato; Tomohiro Murakawa; Kazuhiro Kakimi; Masashi Fukayama; Jun Nakajima
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

4.  Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker.

Authors:  Jong-Baeck Lim; Do-Kyun Kim; Hye Won Chung
Journal:  Cancer Sci       Date:  2014-10-01       Impact factor: 6.716

Review 5.  Targeting chemokine receptors in disease--a case study of CCR4.

Authors:  Roberto Solari; James E Pease
Journal:  Eur J Pharmacol       Date:  2015-05-14       Impact factor: 4.432

6.  Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).

Authors:  Wenguang Wang; Zhilu Gan; Qiang Liu; Shenshen Yan; Rexiti Mulati; Yujie Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.